Endocrine-resistant breast cancer: Underlying mechanisms and strategies for overcoming resistance

Breast Cancer

Volumn 10, Issue 2, 2003, Pages 112-119

  Kurebayashi, Junichi ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

Breast cancer; Endocrine resistance; Growth factor; Hypoxia; Signaling pathway

Indexed keywords

EID: 6044259839     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/BF02967635     Document Type: Review

References (59)

1. Legault-Poisson S, Jolivet J, Poisson R, Poisson R, Beretta-Piccoli M, Band PR: Tamoxifen-induced tumor stimulation and withdrawal response. Cancer Treat Rep 63:1839-1841, 1979. (Pubitemid 10138940)
2. Howell A, Dodwell DJ, Anderson H, Redford J: Response after withdrawal of tamoxifen and progestogens in advanced breast cancer. Ann Oncol 3:611-617, 1992.
3. Gottardis MM, Jordan VC: Development of tamoxifen- stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res 48:5183-5187, 1988.
4. Osborne CK: Mechanisms for tamoxifen resistance in breast cancer: possible role of tamoxifen metabolism. J Steroid Biochem Mol Bio147:83-89, 1993. (Pubitemid 24040944)
5. Ravdin PM, Fritz NF, Tormey DC, Jordan VC: Endocrine status of premenopausal node-positive breast cancer patients following adjuvant chemotherapy and long-term tamoxifen. Cancer Res 48:1026-1029, 1988. (Pubitemid 18061906)
6. Klijn JG, Beex LV, Mauriac L, van Zijl JA, Veyret C, Wildiers J, Jassem J, Piccart M, Burghouts J, Becquart D, Seynaeve C, Mignolet F, Duchateau L: Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. J Natl Cancer Inst 92:903-911, 2000. (Pubitemid 30429190)
7. Jiang SY, Langan-Fahey SM, Stella AL, McCague R, Jordan VC: Point mutation of estrogen receptor (ER) in the ligand-binding domain changes the pharmacology of antiestrogens in ER-negative breast cancer cells stably expressing complementary DNAs for ER. Mol Endocrinol 6:2167-2174, 1992. (Pubitemid 23021567)
8. Schiff R, Reddy P, Ahotupa M, Coronado-Heinsohn E, Grim M, Hilsenbeck SG, Lawrence R, Deneke S, Herrera R, Chamness GC, Fuqua SA, Brown PH, Osborne CK: Oxidative stress and AP-1 activity in tamoxifenresistant breast tumors in vivo. J Natl Cancer Inst 92:1926-1934, 2000. (Pubitemid 32036923)
9. Dumont JA, Bitonti AJ, Wallace CD, Baumann RJ, Cashman EA, Cross-Doersen DE: Progression of MCF-7 breast cancer cells to antiestrogen-resistant phenotype is accompanied by elevated levels of AP-1 DNA-binding activity. Cell Growth Differ 7:351-359, 1996. (Pubitemid 26360774)
10. Johnston SR, Lu B, Scott GK, Kushner PJ, Smith IE, Dowsett M, Benz CC: Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance. Clin Cancer Res 5:251-256, 1999. (Pubitemid 29085176)
11. van Agthoven T, van Agthoven TL, Portengen H, Foekens JA, Dorssers LC: Ectopic expression of epidermal growth factor receptors induces hormone independence in ZR-75-1 human breast cancer cells. Cancer Res 52:5082-5088, 1992.
12. Pietras RJ, Arboleda J, Reese DM, Wongvipat N, Pegram MD, Ramos L, Gorman CM, Parker MG, Sliwkowski MX, Slamon D J: HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10:2435-2446, 1995.
13. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H: Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270:1491-1494, 1995.
14. Bunone G, Briand PA, Miksicek RJ, Picard D: Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBOJ 15:2174-2183, 1996. (Pubitemid 26141134)
15. Chen D, Riedl T, Washbrook E, Pace PE, Coombes RC, Egly JM, All S: Activation of estrogen receptor alpha by Sl18 phosphorylation involves a liganddependent interaction with TFIIH and participation of CDK7. Mol Cell 6:127-137, 2000.
16. Gee JM, Robertson JF, Ellis IO, Nicholson RI: Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. IntJ Cancer 95:247-254, 2001. (Pubitemid 32592092)
17. Kurokawa H, Lenfefink AE, Simpson JF, Pisacane PI, Sliwkowski MX, Forbes JT, Arteaga CL: Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2- overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res 60:5887-5894, 2000.
18. Kurokawa H, Arteaga CL: Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer. Clin Cancer Res 7 (12 Suppl) :4436s-4442s, 2001. (Pubitemid 34031593)
19. Kunisue H, Kurebayashi J, Otsuki T, Tang CK, Kurosumi M, Yamamoto S, Tanaka K, Doihara H, Shimizu N, Sonoo H: Anti-HER2 antibody enhances the growth inhibitory effect of anti-oestrogen on breast cancer cells expressing both oestrogen receptors and HER2. BrJ Cancer 82:46-51, 2000. (Pubitemid 30008957)
20. Martin MB, Franke TF, Stoica GE, Chambon P, Katzenellenbogen BS, Stoica BA, McLemore MS, Olivo SE, Stoica A: A role for Akt in mediating the estrogenic functions of epidermal growth factor and insulin-like growth factor I. Endocrinology 141:4503-4511, 2000. (Pubitemid 32055127)
21. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H: Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem 276:9817-9824, 2001.
22. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, Parsons R: FFEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275:1943-1947, 1997. (Pubitemid 27148818)
23. Chen D, Pace PE, Coombes RC, Ali S: Phosphorylation of human estrogen receptor alpha by protein kinase A regulates dimerization. Mol Cell Biol 19:1002-1015, 1999. (Pubitemid 29046844)
24. Joel PB, Smith J, Sturgill TW, Fisher TL, Blenis J, Lannigan DA: pp90rskl regulates estrogen receptormediated transcription through phosphorylation of Ser-167. Mol Cell Biol 18:1978-1984, 1998. (Pubitemid 28152646)
25. Weis KE, Ekena I~ Thomas JA, Lazennec G, Katzenellenbogen BS: Constitutively active human estrogen receptors containing amino acid substitutions for tyrosine 537 in the receptor protein. Mol Endocrinol 10:1388-1398, 1996. (Pubitemid 26423229)
26. White R, Sjoberg M, Kalkhoven E, Parker MG: Hgand-independent activation of the oestrogen receptor by mutation of a conserved tyrosine. EMBO J 16:1427-1435, 1997. (Pubitemid 27136107)
27. Roodi N, Bailey LR, Kao WY, Verrier CS, Yee CJ, Dupont WD, Parl FF: Estrogen receptor gene analysis in estrogen receptor-positive and receptor-negative primary breast cancer. J Natl Cancer Inst 87:446-451, 1995.
28. Daffada AA, Johnston SR, Smith IE, Smith IE, Detre S, King N, Dowsett M: Exon 5 deletion variant estrogen receptor messenger RNA expression in relation to tamoxifen resistance and progesterone receptor/ pS2 status in human breast cancer. Cancer Res 55:288-293, 1995.
29. Leygue E, Huang A, Murphy LC, Watson PH: Prevalence of estrogen receptor variant messenger RNAs in human breast cancer. Cancer Res 56:4324-4327, 1996. (Pubitemid 26330430)
30. van Dijk MA, Hart AA, van't Veer U: Differences in estrogen receptor alpha variant messenger RNAs between normal human breast tissue and primary breast carcinomas. Cancer Res 60:530-533, 2000. (Pubitemid 30094544)
31. Poola I, Speirs V: Expression of alternatively spliced estrogen receptor alpha mRNAs is increased in breast cancer tissues. J Steroid Biochem Mol Biol 78:459-469, 2001. (Pubitemid 34014827)
32. Graham JD, Bain DL, Richer JK, Jackson TA, Tung L, Horwitz KB: Nuclear receptor conformation, coregulators, and tamoxifen-resistant breast cancer. Steroids 65:579-584, 2000.
33. Webb P, Nguyen P, Shinsako J, Anderson C, Feng W, Nguyen MP, Chen D, Huang SM, Subramanian S, McKinerney E, Katzenellenbogen BS, Stallcup MR, Kushner PJ: Estrogen receptor activation function 1 works by binding p160 coactivator proteins. Mol Endocrinol 12:1605-1618, 1998. (Pubitemid 30665208)
34. Lau OD, Kundu TK, Soceio RE, Ait-Si-Ali S, Khalil EM, Vassilev A, Wolffe AP, Nakatani Y, Roeder RG, Cole PA: HATs off: selective synthetic inhibitors of the histone acetyltransferases p300 and PCAF. Mol Cell 5:589-595, 2000.
35. Lavinsky RM, Jepsen K, Heinzel T, Torchia J, Mullen TM, Schiff R, Del-Rio AL, Ricote M, Ngo S, Gemsch J, Hilsenbeck SG, Osborne CK, Glass CK, Rosenfeld MG, Rose DW: Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sci USA 95:2920-2925, 1998.
36. Jackson TA, Richer JK, Bain DL, Takimoto GS, Tung L, Horwitz KB: The partial agonist activity of antagonist- occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT. Mol Endocrinol 11:693-705, 1997. (Pubitemid 27225297)
37. Mann S, Laucirica R, Carlson N, Younes PS, Ali N, Younes A, Li Y, Younes M: Estrogen receptor beta expression in invasive breast cancer. Hum Pathol 32:113-118, 2001. (Pubitemid 32150637)
38. Jensen EV, Cheng G, Palmieri C, Saji S, Makela S, Van Noorden S, Wahlstrom T, Warner M, Coombes RC, Gustafsson JA: Estrogen receptors and proliferation markers in primary and recurrent breast cancer. Proc Natl Acad Sci USA 98:15197-15202, 2001. (Pubitemid 34019150)
39. Omoto Y, Kobayashi S, Inoue S, Ogawa S, Toyama T, Yamashita H, Muramatsu M, Gustafsson JA, Iwase H: Evaluation of oestrogen receptor beta wield-type and variant protein expression, and relationship with clinicopathological factors in breast cancers. EurJ Cancer 38:380-386, 2002. (Pubitemid 34123315)
40. Marnyama K, Endoh H, Sasaki-Iwaoka H, Kanou H, Shimaya E, Hashimoto S, Kato S, Kawashima H: A novel isoform of rat estrogen receptor beta with 18 amino acid insertion in the ligand binding domain as a putative dominant negative regular of estrogen action. Biochem Biophys Res Commun 246:142-147, 1998. (Pubitemid 28413942)
41. Sonoo H, Kurebayashi J, Iino Y, Inaji H, Watanabe T, Toi M, Kobayashi S, Sato B, Yoshimoto M: Current status and controversial issues concerning endocrine therapy for patients with recurrent breast cancer in Japan. Breast Cancer 6:344-350, 1999.
42. Lapidus RG, Nass SJ, Butash KA, Parl FF, Weitzman SA, Graft JG, Herman JG, Davidson NE: Mapping of ER gene CpG island methylation-specific polymerase chain reaction. Cancer Res 58:2515-2519, 1998. (Pubitemid 28275417)
43. Yoshida T, Eguchi H, Nakachi K, Tanimoto K, Higashi Y, Suemasu K, Iino Y, Morishita Y, Hayashi S: Distinct mechanisms of loss of estrogen receptor alpha gene expression in human breast cancer: methylation of the gene and alteration of trans-acting factors. Carcinogenesis 21:2193-2201, 2000. (Pubitemid 32049225)
44. Kurebayashi J, Otsuki T, Moriya T, Sonoo H: Hypoxia reduces hormone responsiveness of human breast cancer cells. Jpn J Cancer Res 92:1093-1101, 2001. (Pubitemid 33041178)
45. Chia SK, Wykoff CC, Watson PH, Han C, Leek RD, Pastorek J, Gatter KC, Ratcliffe P, Harris AL: Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J Clin Onco119:3660-3668, 2001. (Pubitemid 32786278)
46. Hockel M, Vaupel P: Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 93:266-276, 2001. (Pubitemid 32219813)
47. Nicholson RI, McClelland RA, Gee JM, Manning DL, Cannon P, Robertson JF, Ellis IO, Blarney RW: Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy. Breast Cancer Res Treat 29:117-125, 1994. (Pubitemid 24104843)
48. Houston SJ, Plunkett TA, Barnes DM, Smith P, Rubens RD, Miles DW" Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. Br J Cancer 79:1220-1226, 1999. (Pubitemid 29087902)
49. Leyland-Jones B: Trastuzumab: hopes and realities. Lancet Oncol 3:137-144, 2002.
50. Slamon D, Pegram M: Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin Onco128 (1 Suppl 3):13-19, 2001.
51. Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Janicke F, Miller WR, Evans DB, Dugan M, Brady C, Quebe-Fehling E, Borgs M: Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positlve primary breast cancer: evidence from a phase Ill randomized trial. J Clin Oncol 19:3808-3816, 2001. (Pubitemid 32880059)
52. Stal O, Borg A, Ferno M, Kallstrom AC, Maimstrom P, Nordenskjold B; South Sweden Breast Cancer Group. Southeast Sweden Breast Cancer Group: ErbB2 status and the benefit from two or five years of adjuvant tamoxifen in postmenopausal early stage breast cancer. Ann Oncol 11:1545-1550, 2000. (Pubitemid 32104752)
53. Raben D, Helfrich BA, Chan D, Johnson G, Bunn PA Jr: ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer. Semin Onco129 (1 Suppl 4):37-46, 2002. (Pubitemid 34226517)
54. Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL: Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 61:8887-8895, 2001. (Pubitemid 34013905)
55. Sainsbury JR, Farndon JR, Needham GK, Malcolm AJ, Harris AL: Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet I (8547):1398-1402, 1987. (Pubitemid 17078859)
56. Moasser MM, Basso A, Averbuch SD, Rosen N: The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res 61:7184-7188, 2001. (Pubitemid 32946513)
57. Horwich A, Huddart RA, Gadd J, Boyd PJ, Hetherington JW, Whelan P, Dearnaley DP: A pilot study of intermittent androgen deprivation in advanced prostate cancer. BrJ Uro181:96-99, 1998. (Pubitemid 28316504)
58. Boccardo F, Rubagotti A, Amoroso D, Mesiti M, Romeo D, Caroti C, Farris A, Cruciani G, Villa E, Schieppati G, Mustacchi G; Italian Breast Cancer Cooperative Group: Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: results of an Italian cooperative study. J Clin Oncol 19:4209-4215, 2001. (Pubitemid 33081638)
59. Gandara DR, Lara PN Jr, Goldberg Z, Le QT, Mack PC, Lau DH, Gumerlock PH: Tirapazamine: prototype for a novel class of therapeutic agents targeting tumor hypoxia. Semin Oncol 29 (1 Suppl 4):102-109, 2002 (Pubitemid 34226525)